CClinicalTrials.gg
Status unknownNCT05362669CERCA-SMSUpdated May 5, 2022

SMS Messaging for Invitation in the Cervical Cancer Screening Programme

An interventional study of SMS invitation and Phone call invitation in Cervical Cancer and Human Papilloma Virus, sponsored by Institut Català d'Oncologia. Status unknown at 1 site in Spain. Open to female participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-05.

Sponsored by Institut Català d'Oncologia · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2021, registered May 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
Female
01

Study summary

A study on two different methods of invitation to participate to the cervical cancer screening programme will be conducted within a demonstration project to switch from cytology-based screening to HPV-based screening using self-sampling delivered through the network of pharmacy offices among regular screening attendants in the Barcelona Metropolitana Sud Area, in Catalonia.

At the moment, eligible women are invited to participate to cervical cancer screening via a telephone call invitation explaining the new self-sampling method. Invitation via SMS containing a link to a webpage with information on most frequent questions might be an adequate alternative method that would save costs and workload on human resources.

The aim of this study is to assess the impact on cervical cancer screening participation of an invitation method based on text messaging (SMS).

The invitation method will be evaluated through an interventional trial, in which we will compare the invitation to cervical cancer screening using SMS versus a telephone call invitation explaining the new self-sampling method.

Read the detailed description

Main Hypothesis:

The use of direct SMS without an explanatory call for cervical cancer screening invitation is an acceptable option to invite women if the participation obtained is more than 70% and not less than 15% of the call (current practice).

Specific Hypothesis:

  • Participation in cervical cancer screening programme using SMS invitation is non-inferior to 70%.
  • Participation in cervical cancer screening programme using telephone call is non-inferior to 70%.
  • Participation using SMS invitation is non-inferior to participation using telephone call invitation, considering that an absolute difference less than 15% may not be clinically relevant.

Sample size calculation:

A one-sample non-inferiority test for calculating sample size was performed, assuming a participation rate of 80% using SMS invitation and 85% using telephone call invitation in the cervical cancer screening programme. To detect a participation rate using SMS or telephone call invitation non-inferior to 70%, with a margin of 5%, accepting an alpha risk of 0.025 and a beta risk of 0.2, and 5% of loses of follow-up, we will need 27 women in the telephone call group and 59 women in the SMS group. To observe this non-inferiority by age group (≤40 years, 41-54 years, ≥55 years), 27 and 59 women will be needed for each age group.

To compare both study arms, a two-sample non-inferiority test was performed assuming that using SMS messages to invite women to participate in cervical cancer screening programme will be 5% lower compared to participation when invitation is performed by a phone call (80% versus 85% respectively), although this difference will be non-inferior to 15-15.5%. Thus, if there is a true difference in favor of the telephone call group of 5%, assuming 5% of loses of follow-up, then 450 women will be required (225 in each arm) to be 80% sure that the upper limit of a one-sided 97.5% confidence interval will exclude a difference in favor of the SMS group of more than 15-15.5%.

Randomization procedure:

Women will be randomized in two study arms: intervention (SMS message invitation) and control (telephone call invitation). Randomization will be performed based on permuted blocks of 6 women to ensure equal distribution among age groups.

02

Conditions studied

  • Cervical Cancer
  • Human Papilloma Virus

Keywords

  • Screening
  • Self-sampling
03

In context

Uterine Cervical Neoplasms

1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.

This study's planned enrollment of 450 is above the median of 100 across 1,377 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Institut Català d'Oncologia is the lead sponsor of 35 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Eligible women for cervical cancer screening aged 30 to 65 years of age.
  • Registered at the Health Care Database (RCA).

Exclusion criteria

Exclusion Criteria:

  • Individuals without a mobile phone number registered at the RCA.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Experimental - Intervention

    SMS invitation to participate in cervical cancer screening using HPV self-sampling.

    Behavioral: SMS invitation

  • Active comparator
    Active Comparator - Usual Care

    Phone call invitation to participate in cervical cancer screening using HPV self-sampling.

    Behavioral: Phone call invitation

Interventions

  • BehavioralSMS invitation

    Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.

  • BehavioralPhone call invitation

    Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.

06

What researchers measure

Primary outcomes

  1. Participation in cervical cancer screening program

    Participation (no/yes) in cervical cancer screening program will be gathered prospectively 12 weeks after sending the screening invitation (day 0).

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Institut Català d'Oncologia
    L'Hospitalet de Llobregat, Catalunya, Spain 08908, Spain
    • Paula Peremiquel-Trillas, MD MPH PhDc · Contact · paula.peremiquel@iconcologia.net · +34932607812
    • Esther Roura Fornells, MPH PhD · Contact · eroura@iconcologia.net · +34932607812
    • Paula Peremiquel-Trillas, MD, MPH, PhDc · Principal investigator
    • Esther Roura Fornells, MPH, PhD · Principal investigator
    • Laia Bruni Coccoz, MD, MPH, PhD · Sub investigator
    • Clàudia Robles Hellín, MPH, PhD · Sub investigator
    • Raquel Ibáñez, MPH, PhD · Sub investigator
    • Laura Monfil, BSc · Sub investigator
    • Maite Carvajal, RN · Sub investigator
    • Rebeca Font · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05362669
Lead sponsor
Institut Català d'Oncologia
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Nov 8, 2021
Primary completion
May 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
May 5, 2022

Study contacts

Paula Peremiquel-Trillas, MD, MPH, PhDc
Contact
paula.peremiquel@iconcologia.net
+34932607812 ext. 3118
Esther Roura Fornells, MPH, PhD
Contact
eroura@iconcologia.net
+34932607812 ext. 3185
Paula Peremiquel-Trillas, MD, MPH, PhDc
principal investigator · Institut Català d'Oncologia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion